Medigus endoscopy platform for GERD eyes worldwide clinical adoption

Feb. 13, 2014
Minimally invasive endoscopy device maker Medigus is working to launch its MUSE endoscopy platform commercially worldwide, which treats gastroesophageal reflux disease (GERD) without the need for incision.

Minimally invasive endoscopy device maker Medigus (Omer, Israel) is working to launch its MUSE endoscopy platform commercially worldwide, which treats gastroesophageal reflux disease (GERD) without the need for incision.

Related: Advanced OCT: Next-gen OCT for the esophagus

The platform features a single-use surgical endostapler equipped with the company's miniature camera, an ultrasonic sight, and a rangefinder to perform surgical anterior fundoplication in a less invasive way compared to other methods. The approach uses standard surgical staples with clinical data comparable to current surgical procedures. What's more, it is an outpatient procedure that could potentially eliminate lifelong medication, in addition to less hospital readmissions and hospitalizations and reduced costs to the healthcare system.

In addition to the nearly 100,000 laparoscopic anti-reflux procedures performed in the U.S., the potential for the MUSE platform in the U.S., which comprises about 20 percent of the global market, is roughly 24 million GERD patients.

The company will continue to provide ongoing commercial and clinical validation regarding the platform's safety, efficacy, and cost value, supported by upcoming data and expected journal publications including abstracts at the 2014 Society of American Gastrointestinal and Endoscopic Surgeons (SAGES) and Digestive Disease Week (DDW) medical meetings, explains CEO Chris Rowland.


Follow us on Twitter, 'like' us on Facebook, and join our group on LinkedIn

Subscribe now to BioOptics World magazine; it's free!

About the Author

BioOptics World Editors

We edited the content of this article, which was contributed by outside sources, to fit our style and substance requirements. (Editor’s Note: BioOptics World has folded as a brand and is now part of Laser Focus World, effective in 2022.)

Sponsored Recommendations

Next generation tunable infrared lasers

Nov. 28, 2023
Discussion of more powerful and stable quantum cascade tunable infrared lasers, applications, and test results.

What AI demands mean for data centers

Nov. 28, 2023
The 2023 Photonics-Enabled Cloud Computing Summit assembled by Optica took an aggressive approach to calling out the limitations of today’s current technologies.

SLP feature for lighting control available on cameras offering

Nov. 28, 2023
A proprietary structured light projector (SLP) feature is now available on the company’s camera series, including the ace 2, boost R, ace U, and ace L.

Chroma Customer Spotlight - Dr. David Warshaw, About his Lab

Nov. 27, 2023
David Warshaw, Professor and Chair of Molecular Physiology and Biophysics at the University of Vermont (UVM), walks us through his lab. Learn about his lab’s work with the protein...

Voice your opinion!

To join the conversation, and become an exclusive member of Laser Focus World, create an account today!